Increased expression of latent TGF-beta binding protein-1 and fibrillin-1 in human uterine leiomyomata.
We compared latent TGF-ss binding protein-1 (LTBP-1) and fibrillin-1 (FBN-1) expression in leiomyomata and myometrium, correlated with leiomyomata size. We studied in vivo and in vitro effects of ovarian steroids using matched leiomyomata and myometrium samples from both phases of the menstrual cycle. Leiomyomata were divided into small (<or=2 cm), medium (3-5 cm) and large (>or=6 cm) groups. We validated LTBP-1 and FBN-1 expression using QPCR, western blot and immunohistochemistry. LTBP-1 and FBN-1 mRNA and protein expressions were higher in the medium-sized group compared with myometrium in the proliferative phase (P = 0.01; P = 0.01). FBN-1 mRNA expression was higher in the secretory phase (P = 0.01). LTBP-1 mRNA and protein expression was higher in the medium group compared with the small and large groups in the proliferative phase (P = 0.04; P = 0.04). No differences between groups were seen in FBN-1 expression in either phase. 17Beta-estradiol (E2) increased mRNA and protein expression of LTBP-1 and FBN-1 in cultured leiomyoma smooth muscle cells (LSMC) (P < 0.05). No change in FBN-1 and LTBP-1 expression was observed when cells were treated with E2 plus progesterone. Estrogen may be involved in LTBP-1 and FBN-1 expression in leiomyomata. Extracellular matrix metabolism may be different in medium-sized leiomyoma.
Zhao
Yangyu
Y
Department of Obstetrics and Gynecology, Stanford University School of Medicine, Stanford, CA, USA.
Wen
Yan
Y
Polan
Mary Lake
ML
Qiao
Jie
J
Chen
Bertha H
BH
D004958:Estradiol / Q000494:pharmacology; D005260:Female; D000071838:Fibrillin-1; D000071837:Fibrillins; D015972:Gene Expression Regulation, Neoplastic / Q000187:drug effects; D006801:Humans; D053779:Latent TGF-beta Binding Proteins / Q000235:genetics / Q000378:metabolism*; D007889:Leiomyoma / Q000235:genetics / Q000378:metabolism* / Q000473:pathology; D008840:Microfilament Proteins / Q000235:genetics / Q000378:metabolism*; D009215:Myometrium / Q000187:drug effects / Q000378:metabolism; D011374:Progesterone / Q000494:pharmacology; D011372:Progestins / Q000494:pharmacology; D012333:RNA, Messenger / Q000378:metabolism; D014594:Uterine Neoplasms / Q000235:genetics / Q000378:metabolism* / Q000473:pathology; D054392:Adipokines
D004958:Estradiol; D000071838:Fibrillin-1; D000071837:Fibrillins; D053779:Latent TGF-beta Binding Proteins; D008840:Microfilament Proteins; D011374:Progesterone; D011372:Progestins; D012333:RNA, Messenger; C000605722:FBN1 protein, human; D054392:Adipokines; C509032:LTBP1 protein, human